Cholesteatoma is a destructive lesion of the temporal bone that gradually expands and causes complications by erosion of the adjacent bony structures. Bone resorption can result in destruction of the ossicular chain and otic capsule with consecutive hearing loss, vestibular dysfunction, facial paralysis and intracranial complications. Surgery is the only treatment of choice. The etiopathogenesis of cholesteatoma, however, is still controversial. This review was designed to understand the reasons for these disparities and to reduce or eliminate them. Future studies focused on developmental, epidemiological, hormonal and genetic factors as well as on treatment are likely to contribute to further understanding of cholesteatoma pathogenesis.

ReviewThe aims of the European Academy of Otology and Neurootology/Japan Otological Society (EAONO/JOS) Joint Consensus Statements on Definition, Classification and Staging are as follows:1. The definitions provide terminologies in the description of cholesteatoma. 2. The classification categorized cholesteatoma into distinct categories to facilitate the comparison of surgical outcomes across reports. 3. The staging system reflects the severity of the cholesteatoma, the difficulty to achieve complete removal, and the subsequent restoration of normal function.The authors wish to present the final consensus first, followed by an explanation of the methodology on how the EAONO/JOS consensus was reached by the steering group.The clinical classification of middle ear mucosa is summarized in Figure 1. 1 EAONO/JOS Joint Consensus Statements on the Definitions, Classification and Staging of Middle Ear CholesteatomaThe European Academy of Otology and Neurotology (EAONO) has previously published a consensus document on the definitions and classification of cholesteatoma. It was based on the Delphi consensus methodology involving the broad EAONO membership. At the same time, the Japanese Otological Society (JOS) had been working independently on the "Classification and Staging of Cholesteatoma." EAONO and JOS then decided to collaborate and produce a joint consensus document. The EAONO/JOS joint consensus on "Definitions, Classification and Staging of Middle Ear Cholesteatoma" was formally presented at the 10th International Conference on Cholesteatoma and Ear Surgery in Edinburgh, June 5-8, 2016. The international otology community who attended the consensus session was given the chance to debate and give their support or disapproval. The statements on the "Definitions of Cholesteatoma" received 89% approval. The "Classification of Cholesteatoma" received almost universal approval (98%). The "EAONO/JOS Staging System on Middle Ear Cholesteatoma" had a majority of approval (75%). Some international otologists wanted to see more prognostic factors being incorporated in the staging system. In response to this, the EAONO/JOS steering group plans to set up an "International Otology Outcome Working Group" to work on a minimum common otology data set that the international otology community can use to evaluate their surgical outcome. This will generate a large database and help identify relevant prognostic factors that can be incorporated into the staging system in future revisions. KEYWORDS:2 J Int Adv Otol 2017; 13(1): 1-8 Definitions and Statements on Cholesteatoma1. Cholesteatoma is a mass formed by the keratinizing squamous epithelium in the tympanic cavity and/or mastoid and subepithelial connective tissue and by the progressive accumulation of keratin debris with/without a surrounding inflammatory reaction.2. Cholesteatoma consists of matrix (keratinizing squamous epithelium), perimatrix (varying thickness of the subepithelial connective tissue), and keratin debris.3. The pathophysiology of cholesteatoma is not completel...

Better surgical field conditions were the results of the powerful anti-inflammatory and antiedematous activity of the drug, which facilitated blood and secretion evacuation from the operated area and prevented the optic system from staining.

The study objective was clinical assessment of the efficacy of photodynamic therapy (PDT) in the treatment of oral lichen planus (OLP). There were 23 patients aged 31–82 included in the study with oral lichen planus diagnosed clinically and histopathologically. In all patients photodynamic therapy was performed with the use of chlorin e6 (Photolon®), containing 20 % chlorin e6 and 10 % dimethyl sulfoxide as a photosensitizer. PDT was performed using a semiconductor laser, with power up to 300 mW and a wavelength of 660 nm. A series of illumination sessions was conducted with the use of superficial light energy density of 90 J/cm2. Changes of lesion size were monitored at one, two, five, and ten PDT appointments from the series of ten according to the authors' own method. The sizes of clinical OLP lesions exposed to PDT were reduced significantly (on average by 55 %). The best effects were observed for the lesions on the lining mucosa (57.6 %). The therapy was statistically significantly less effective when masticatory mucosa was affected (reduction, 30.0 %). Due to substantial efficacy and noninvasiveness, PDT can be useful in the treatment of OLP lesions.

Objectives/Hypothesis Our objective was to determine whether drug‐induced sleep apnea (DISE) affects the successfulness of the surgical outcome. Study Design Prospective, seven‐country, nonrandomized trial. Methods There were 326 consecutive obstructive sleep apnea (OSA) patients who had nose, palate, and/or tongue surgery included in the study. DISE was performed in only one group. Results There were 170 patients in the DISE group and 156 patients in no‐DISE group. The mean preoperative body mass index (BMI) for the DISE group was 27.6 ± 4.6, whereas in the no‐DISE group it was 28.1 ± 3.9 (P = .23). The mean preoperative systolic blood pressure (SBP) for the DISE group was 130.4 ± 16.7, whereas in the no‐DISE group it was 142.9 ± 15.5 (P < .001). The mean preoperative diastolic blood pressure (DBP) for the DISE group was 81.4 ± 9.7, whereas in the no‐DISE group it was 89.1 ± 9.7 (P < .001). The mean preoperative apnea‐hypopnea index (AHI) for the DISE group was 32.6 ± 18.8, whereas in the no‐DISE group it was 33.7 ± 19.6 (P = .61). The mean postoperative AHI for the DISE group was 15.9 ± 12.6, whereas in the no‐DISE group it was 13.2 ± 8.8 (P = .023). The age‐, gender‐, BMI‐adjusted percentage change in AHI for the DISE group was −48.4 ± 31.9, whereas in the no‐DISE group it was −59.8 ± 18.6 (P < .001). The age‐, gender‐, and BMI‐adjusted success rate for the DISE group was 66.5%, whereas in the no‐DISE group it was 80.8% (P = .004). The age‐, gender‐, and BMI‐adjusted change in SBP for the DISE group was −6.1 ± 8.6, whereas in the no‐DISE group it was −13.3 ± 11.1 (P < .001). The age‐, gender‐, and BMI‐adjusted change in DBP in the DISE group was −5.2 ± 12.1, whereas in the no‐DISE group it was −12.4 ± 11.7 (P < .001). The mean age‐ and gender‐adjusted change in BMI for the DISE group was −4.6 ± 12.9, whereas in the no‐DISE group it was −6.3 ± 18.5 (P = .34). The Cohen effect of BMI on the overall AHI, lowest oxygen saturation, and blood pressure changes was 0.08. Conclusions DISE may not significantly affect surgical success in OSA. Level of Evidence 2c Laryngoscope, 130:551–555, 2020